Drug intelligence / Profile preview

SBP-9881

Development stage: Preclinical
Lead developer: Camino Pharma
Modality: Small Molecules
Administration: Oral

Overview

SBP-9881 is an investigational, orally bioavailable small-molecule neuropsychiatric drug being developed by Camino Pharma for the treatment of depression and related mood disorders characterized by anhedonia and avolition. Preclinical data highlighted by the company indicate that SBP-9881 produces fast-acting and long-lasting antidepressant-like effects in vivo, and it is being validated in novel rodent models of anhedonia and avolition with support from a Small Business Innovation Research (SBIR) grant from the U.S. National Institute of Mental Health. Detailed molecular target, precise mechanism of action, and human clinical development status have not been publicly disclosed.

Targets

GRM3 (mGluR3)GRM2 (mGluR2)

Beyond the preview

Go deeper on SBP-9881.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBP-9881.

Explore the full profile